Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy
Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy
复制标题
DOI：
10.1177/112067210801800427
复制
发表时间：
2008-07-01
影响因子：
1.7
通讯作者：
Garcia-Sanchez, J.
中科院分区：
文献类型：
--
作者：
Reche-Frutos, J.;Calvo-Gonzalez, C.;Garcia-Sanchez, J.
目的.评估玻璃体腔注射雷珠单抗治疗息肉状脉络膜血管病变的短期解剖学效果。所有患者均接受了全面的眼科检查。每月注射雷珠单抗，持续3个月。在第三个月的雷珠单抗注射后1个月进行吲哚菁血管造影（ICG）和光学相干断层扫描（OCT）。ICG血管造影显示9/13个病灶（69.2%）息肉消失。OCT显示视网膜厚度显著降低（p = 0.02）。在我们的系列中，我们注意到在初次和最终访视之间，视网膜下积液（p = 0.02）和色素上皮脱离（0.016）的患者百分比显著降低。此外，我们注意到BCVA显著增加（p = 0.02）。每月玻璃体内注射雷珠单抗3个月具有短期有益的解剖效果。(Eur J Ophthalmol 2008; 18：645 - 8）
PURPOSE. To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.METHODS. All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.RESULTS. Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p=0.02).CONCLUSIONS. Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect. (Eur J Ophthalmol 2008; 18: 645-8)